Cornelis M. Melief
Leiden, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 97 publications
Therapeutic vaccination for active induction of T cell immunity against cancer, ready for a rich harvest after 40 years.
Journal: Journal for immunotherapy of cancer
Published: February 10, 2026
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer.
Journal: Journal for immunotherapy of cancer
Published: August 22, 2025
Dysfunctional CD4 T cells in an oncovirus-specific TCR-transgenic in vivo model.
Journal: Nature communications
Published: April 01, 2025
Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial.
Journal: Gynecologic oncology
Published: December 23, 2024
Delayed vaccine-induced CD8+ T cell expansion by topoisomerase I inhibition mediates enhanced CD70-dependent tumor eradication.
Journal: Journal for immunotherapy of cancer
Published: November 05, 2023
Induction of broad multifunctional CD8+ and CD4+ T cells by hepatitis B virus antigen-based synthetic long peptides ex vivo.
Journal: Frontiers in immunology
Published: February 10, 2023
Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV+ Men.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 31, 2023
Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides.
Journal: Cancer immunology, immunotherapy : CII
Published: January 27, 2023
Combination immunotherapy with synthetic long peptides and chemotherapy or PD-1 blocker for cancers caused by human papilloma virus type 16.
Journal: Seminars in immunopathology
Published: January 24, 2023
Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?
Journal: Cell reports. Medicine
Published: October 19, 2022
Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions.
Journal: Journal for immunotherapy of cancer
Published: September 17, 2022
Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4+ and CD8+ T cells for immunotherapy of cancer.
Journal: Journal for immunotherapy of cancer
Published: July 17, 2022
Last Updated: 09/26/2026